Business Context and Reporting Period
Protalix Biotherapeutics, Inc. filed this Form 8-K on September 14, 2009, to report a significant corporate event. The Company is a biopharmaceutical firm incorporated in Florida with principal executive offices in Carmiel, Israel.
Key Financial Metrics
This filing is a Current Report regarding a specific event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The material change reported is the completion of the pivotal Phase III clinical trial for prGCD, the Company's proprietary plant-cell expressed recombinant form of glucocerebrosidase (GCD) intended for the treatment of Gaucher disease. Additionally, the Company announced that the proposed brand name for prGCD is UPLYSO.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, outlook, or a discussion of risks and contingencies beyond the announcement of the trial completion. The event itself represents a critical milestone in the Company's product development pipeline.
Investor Verification Checklist
- Verify the clinical data and statistical significance of the completed Phase III trial for prGCD.
- Confirm the regulatory submission timeline for UPLYSO following the trial completion.
- Review the attached press release (Exhibit 99.1) for detailed trial results not included in the 8-K summary.
- Assess the potential impact of this milestone on the Company's cash burn rate and future financing needs.